Finance News

Hims & Hers Shares Plunge After Q3 Loss and Weak Outlook, Even as Revenue Jumps 49%

Hims & Hers shares fell sharply after the telehealth company reported its third quarter results on November 9, 2026. Revenue jumped 49% from a year earlier, but the company swung to a $33 million loss, its profit margins shrank, and its outlook for the rest of the year came in below what Wall Street expected. Shares fell about 12% on November 9 and another 17% on November 10, closing at $19.13.

What happened

Hims & Hers reported revenue of $890.4 million for the third quarter of 2026, up 49% from $599 million in the same quarter a year earlier. That was roughly in line with what analysts expected. The problem was profit. The company lost $33 million in the quarter, compared with a $15.8 million profit a year ago, and reported a loss of 14 cents per share where analysts had expected a profit of 6 cents.

Margins were the main reason. Gross margin, the share of each sales dollar left after the direct cost of providing the service, fell to 57% from 74% a year earlier. The company is selling more branded weight loss drugs, which carry lower margins than its older products, and the cost of revenue rose 143% while revenue rose 49%. Adjusted earnings before interest, tax, depreciation and amortisation, a measure of underlying profit, were $82.4 million, a 9% margin.

Subscriber numbers also disappointed. Subscribers grew 13% from a year earlier to about 2.79 million, but that was down from 2.89 million in the previous quarter, a drop of about 100,000. The company also said $18 million of weight loss membership revenue was deferred and will be counted in the fourth quarter instead.

The outlook made things worse. Hims & Hers guided fourth quarter revenue of $875 million to $895 million, well below the $953 million analysts expected, and cut its full year adjusted earnings guidance to $257 million to $277 million, down from $275 million to $325 million.

The sell-off came just days after good news had lifted the stock. On November 6, shares jumped 8% after Eli Lilly agreed to sell its weight loss drugs Zepbound and Foundayo directly on Hims & Hers, as covered in our post on that deal (https://investclaritypath.com/eli-lilly-zepbound-foundayo-hims-hers-november-2026/). Fierce Healthcare reported the results on November 10, 2026, and StockStory reported the same figures and the share price fall.

Why it matters for beginners

This is a useful example of why rising sales do not always lift a share price. Investors care about profit, not just revenue. A company can sell much more and still lose money if the cost of each sale rises faster than sales, which is what happened here as lower margin weight loss drugs became a bigger part of the business.

Guidance matters too. Guidance is a company’s own forecast for the next quarter or the full year. When a company cuts its forecast, investors often sell, because the future they were paying for now looks smaller. Hims & Hers did both things investors dislike at once: it missed on profit and it lowered its outlook.

The subscriber drop is a third warning sign. For a subscription business, fewer subscribers than the previous quarter suggests growth is slowing, even if the year on year number still looks strong.

What to watch next

Watch the fourth quarter results, due in early 2027, to see whether the $18 million of deferred weight loss revenue arrives and whether margins stop falling. Gross margin was 74% a year ago, 64% in the second quarter, and 57% now, so the trend is the key number.

Watch subscriber numbers too. Another quarterly drop would suggest the slowdown is continuing. Also watch whether the Eli Lilly deal, which lets Hims & Hers sell branded weight loss drugs at Lilly’s own prices, brings in new customers without squeezing margins further.

FAQ

What is Hims & Hers?

Hims & Hers is a US telehealth company that sells health and wellness products online, including hair loss, skin care, sexual health, and weight loss treatments, through a subscription model.

How can revenue rise 49% and the share price still fall?

Because profit fell. Revenue is the money coming in, but profit is what is left after costs. Hims & Hers lost $33 million in the quarter as the cost of each sale rose much faster than sales, and it also cut its forecast for the rest of the year.

What is gross margin?

Gross margin is the share of each sales dollar left after the direct cost of providing a product or service. A fall from 74% to 57% means the company keeps 57 cents of every dollar now, down from 74 cents a year ago.

What is guidance?

Guidance is a company’s own forecast for future revenue and profit. Investors compare it with what analysts expected. When guidance comes in below expectations, the share price often falls.

Sources

Fierce Healthcare, Hims & Hers tightens 2026 outlook after Q3 misses, November 10, 2026: https://www.fiercehealthcare.com/finance/hims-hers-reports-8904m-q3-revenue-tightens-2026-outlook
StockStory, Why Hims & Hers Health (HIMS) shares are getting obliterated today, November 10, 2026: https://stockstory.org/us/stocks/nyse/hims/news/why-up-down/why-hims-and-hers-health-hims-shares-are-getting-obliterated-today-3
The Cheap Investor, Hims & Hers Grew Revenue 49%. Why Did the Stock Drop 15%?, November 10, 2026: https://thecheapinvestor.com/2026/11/10/hims-hers-grew-revenue-49-why-did-the-stock-drop-15/

This article is for general information and education only. It is not legal or financial advice.

Invest Clarity Path Team

Invest Clarity Path Team writes beginner personal finance guides at Invest Clarity Path, educational only, no financial advice.

Leave a Reply

Your email address will not be published. Required fields are marked *

Never miss a story

Get our latest reporting delivered to your inbox.